Vinorelbine combined with cisplatin in advanced stage non-small-cell lung cancer
- VernacularTitle:长春瑞滨联合顺铂方案治疗晚期非小细胞肺癌
- Author:
Meina WU
;
Xuyi LIU
;
Jian FANG
- Publication Type:Journal Article
- Keywords:
advance stage non-sraall-cell lung cancer;
vinorelbine;
cisplatin;
chemotherapy
- From:China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To evaluate the efficacy and toxicity of vinorelbine combined with cisplatin (NP regimen) in the treatment of advanced non-small-cell lung cancer ( NSCLC). Methods: ninety-one patients with advanced NSCLC were confirmed by pathology or cytology. There were 56 patients with lung adenocarcinoma, 27 with squamous carcinoma and 4 with alveoli cell cancer, 3 with large-cell lung cancer, one case diagnosed by cytological smear section. The eighty patients had no prior chemotherapy and 11 were those without received previously chemotherapy. Thirty-two patients had stage Ⅲ disease and 59 had stage Ⅳ. Results: Partial response was observed in 37 patients with an overall response rate of 40. 7% (95%CI:30. 5%-50. 7%). Median time to progression (TTP) were 5 months(95% CI: 4-6 months). Median survival duration was 13 months (95% CI: 11-15months), one-year survival rate was 52. 7% ( CI: 42. 4%-62. 9%). The dose limiting toxicity was neutropenia that was observed in 87. 9% of the patients (40.7% in grades Ⅲ and Ⅳ). The remission response rate is 40. 6% , TTP is 5 months, MS is 13 months and 1-year survival rate was 52.7% . Conclusions: The results indicate NP regimen for advanced NSCLC is promise, and the toxicities are tolerable.
